The epidemiology of candidemia in two United States cities: results of a population-based active surveillance - PubMed (original) (raw)

. 1999 Nov;29(5):1164-70.

doi: 10.1086/313450.

M E Brandt, W R Pruitt, L A Conn, B A Perkins, D S Stephens, W S Baughman, A L Reingold, G A Rothrock, M A Pfaller, R W Pinner, R A Hajjeh

Affiliations

• PMID: 10524958
• DOI: 10.1086/313450

The epidemiology of candidemia in two United States cities: results of a population-based active surveillance

A S Kao et al. Clin Infect Dis. 1999 Nov.

Abstract

We conducted prospective, active population-based surveillance for candidemia (defined as any Candida species isolated from blood) in Atlanta and San Francisco (total population, 5.34 million) during 1992-1993. The average annual incidence of candidemia at both sites was 8 per 100,000 population. The highest incidence (75 per 100,000) occurred among infants </=1 year old. In 19% of patients, candidemia developed prior to or on the day of admission. Underlying medical conditions included cancer (26%), abdominal surgery (14%), diabetes mellitus (13%), and human immunodeficiency virus infection (10%). In 47% of cases, species of Candida other than Candida albicans were isolated, most commonly Candida parapsilosis, Candida glabrata, and Candida tropicalis. Antifungal susceptibility testing of 394 isolates revealed minimal levels of azole resistance among C. albicans, C. tropicalis, and C. parapsilosis. These data document the substantial burden of candidemia and its changing epidemiology. Continued surveillance will be important to monitor the epidemiology of candidemia and to detect emergence of resistance to azoles.

PubMed Disclaimer

Comment in

• Estimating the cost of nosocomial candidemia in the united states.
  Miller LG, Hajjeh RA, Edwards JE Jr. Miller LG, et al. Clin Infect Dis. 2001 Apr 1;32(7):1110. doi: 10.1086/319613. Clin Infect Dis. 2001. PMID: 11264044 No abstract available.

Similar articles

• Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
  Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM. Horn DL, et al. Clin Infect Dis. 2009 Jun 15;48(12):1695-703. doi: 10.1086/599039. Clin Infect Dis. 2009. PMID: 19441981
• Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
  Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O; AmarCand Study Group. Leroy O, et al. Crit Care Med. 2009 May;37(5):1612-8. doi: 10.1097/CCM.0b013e31819efac0. Crit Care Med. 2009. PMID: 19325476
• Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
  Krcmery V, Barnes AJ. Krcmery V, et al. J Hosp Infect. 2002 Apr;50(4):243-60. doi: 10.1053/jhin.2001.1151. J Hosp Infect. 2002. PMID: 12014897 Review.
• The north and south of candidemia: Issues for Latin America.
  Colombo AL, Thompson L, Graybill JR. Colombo AL, et al. Drugs Today (Barc). 2008 Sep;44 Suppl A:1-34. Drugs Today (Barc). 2008. PMID: 18810276 Review.

Cited by

• Trafficking of phagocytic peritoneal cells in hypoinsulinemic-hyperglycemic mice with systemic candidiasis.
  Fraga-Silva TF, Venturini J, de Arruda MS. Fraga-Silva TF, et al. BMC Infect Dis. 2013 Mar 25;13:147. doi: 10.1186/1471-2334-13-147. BMC Infect Dis. 2013. PMID: 23521724 Free PMC article.
• Population-Based Active Surveillance for Culture-Confirmed Candidemia - Four Sites, United States, 2012-2016.
  Toda M, Williams SR, Berkow EL, Farley MM, Harrison LH, Bonner L, Marceaux KM, Hollick R, Zhang AY, Schaffner W, Lockhart SR, Jackson BR, Vallabhaneni S. Toda M, et al. MMWR Surveill Summ. 2019 Sep 27;68(8):1-15. doi: 10.15585/mmwr.ss6808a1. MMWR Surveill Summ. 2019. PMID: 31557145 Free PMC article.
• Pseudomonas aeruginosa, Candida albicans, and device-related nosocomial infections: implications, trends, and potential approaches for control.
  Pierce GE. Pierce GE. J Ind Microbiol Biotechnol. 2005 Jul;32(7):309-18. doi: 10.1007/s10295-005-0225-2. Epub 2005 May 3. J Ind Microbiol Biotechnol. 2005. PMID: 15868157 Review.
• Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients.
  Mullen CA, Abd El-Baki H, Samir H, Tarrand JJ, Rolston KV. Mullen CA, et al. Support Care Cancer. 2003 May;11(5):321-5. doi: 10.1007/s00520-003-0453-9. Epub 2003 Mar 11. Support Care Cancer. 2003. PMID: 12720076
• Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity.
  Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Louie A, et al. Antimicrob Agents Chemother. 2005 Dec;49(12):5058-68. doi: 10.1128/AAC.49.12.5058-5068.2005. Antimicrob Agents Chemother. 2005. PMID: 16304173 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information